Study shows women may lose bone density with drug
Feb 8, 2012
A new study conducted by researchers at the University Health Network in Toronto found that the drug exemestane, which is used to treat breast cancer, may worsen bone loss in postmenopausal women.
The researchers found that even though the drug, also known as aromasin, reduced the odds of breast cancer recurring by 65 percent, it could reduce bone density three times in older women who are being treated with the drug. The researchers believe more studies have to be done, and that women should not stop taking the drug because of the bone loss.
"Women considering exemestane for the primary prevention of breast cancer should weigh their individual risks and benefits," the researchers conclude. "For women taking exemestane, regular bone monitoring plus adequate calcium and vitamin D supplementation are important."
According to the American Cancer Society, this disease is the second leading cause of cancer-related death among women, following only lung cancer. However, the death rate has been decreasing since 1990 due to advancements in research and breakthrough breast cancer news. There are currently 2.5 million survivors in the United States.